Nitroxoline tablets, film-coated, 50 mg each, No. 50 (10 x 5)
Ingredients
Active ingredient: nitroxoline;
1 tablet contains 50 mg of nitroxoline (calculated as 100% dry substance);
excipients: potato starch, lactose monohydrate, calcium stearate, colloidal anhydrous silicon dioxide, talc;
film coating 85F35260 Opadry II Red: partially hydrolyzed polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide (E 171), Special Red AG (E 129), Sunset Yellow FCF (E 110).
Dosage Form
Film-coated tablets.
Main physical and chemical properties: round tablets with a biconvex surface, coated with a red film coating.
Pharmacotherapeutic group
Antimicrobial agents for systemic use. Other antibacterial agents. ATC code J01X X07.
Pharmacological properties
Pharmacodynamics.
A broad-spectrum antimicrobial and antiprotozoal agent for the treatment of urinary tract infections. Nitroxoline selectively inhibits bacterial DNA synthesis, forms complexes with metal-containing enzymes in microbial cells, and is active against Gram-positive microorganisms such as Staphylococcus spp. (including S. aureus), Streptococcus spp. (including beta-hemolytic streptococci, Streptococcus pneumoniae, and Enterococcus faecalis), Corynebacterium spp., Bacillus subtilis, as well as against Gram-negative microorganisms such as N. gonorrhoeae, E. coli, Proteus spp., Klebsiella spp., Salmonella spp., Shigella spp., and Enterobacter spp.
Nitroxoline is also active against Mycobacterium tuberculosis, Trichomonas vaginalis, and certain species of fungi (Candida spp., dermatophytes, molds, and some causative agents of deep mycoses).
Pharmacokinetics.
After oral administration, it is well absorbed from the gastrointestinal tract. It is excreted primarily by the kidneys in an unchanged form. Following a single 100-mg dose, the minimum bacteriostatic concentration in urine persists for up to 3 hours; following a 400-mg dose, it persists for up to 7 hours.
Indications
- Acute, chronic, and recurrent urinary tract infections caused by Gram-positive and Gram-negative microorganisms and fungi susceptible to nitroxoline.
- Prevention of recurrent urinary tract infections.
Before prescribing the drug, a microbiological test must be performed to identify the infectious agent and determine its susceptibility to nitroxoline. However, if there is reason to believe that the infection is most likely caused by microorganisms sensitive to Nitroxoline, treatment may be initiated before test results are available.
Contraindications
- Hypersensitivity to nitroxoline or to any other component of the drug, as well as to other quinolines;
- severe hepatic and renal insufficiency (creatinine clearance less than 0.33 mL/s).
Drug Interactions and Other Interactions
Tetracycline-class drugs: additive effects of each drug are observed; with nystatin and levorin—potentiation of action.
Magnesium-containing antacids: absorption of nitroxoline is slowed.
Nitrofurans: Concomitant use is not possible due to the additive negative neurotropic effect.
Nalidixic acid: reduced efficacy.
Hydroxyquinolines or their derivatives: should not be used concurrently.
Special Considerations for Use
Use with caution in patients with impaired renal function due to the potential for nitroxoline accumulation, and in patients with cataracts.
Cases of peripheral neuritis and optic neuritis have been reported with repeated and prolonged treatment with high doses of halogenated hydroxyquinoline derivatives. Nitroxoline is a nitro derivative of quinoline, and such side effects have not been observed with it; however, caution is recommended when treating with nitroxoline—such patients should be under close medical supervision.
Treatment should not exceed 4 weeks without additional medical evaluation.
The drug contains the dye “Sunset Yellow FCF” (E 110), which may cause allergic reactions, including bronchial asthma. The risk of an allergic reaction is higher in patients with hypersensitivity to acetylsalicylic acid.
The drug contains lactose; therefore, patients with hereditary forms of galactose intolerance, glucose-galactose malabsorption syndrome, or lactase deficiency should not use this drug.
Since the drug is excreted by the kidneys, urine turns saffron-yellow during treatment with nitroxoline.
Use During Pregnancy or Breastfeeding.
The safety and efficacy of this medication during pregnancy or breastfeeding have not been established; therefore, nitroxoline should not be prescribed during these periods.
Effect on reaction time when operating motor vehicles or other machinery.
There is no evidence that this medication may adversely affect reaction time in drivers or individuals operating machinery.
Dosage and Administration
Adults: The average recommended daily dose is 400 mg (2 tablets 4 times daily before meals). For severe conditions, the daily dose may be increased to 800 mg (4 tablets 4 times a day). The maximum daily dose for adults is 800 mg.
Children aged 3 to 5 years: The recommended daily dose is 200 mg (1 tablet 4 times a day).
Children 5 years of age and older: the recommended daily dose is 200–400 mg (1–2 tablets 4 times a day).
The duration of treatment is 2–3 weeks.
Patients may take the medication continuously for 1 month. For chronic infections, the medication should be prescribed in repeated 2-week courses with 2-week breaks (the course of treatment may last several months).
Renal impairment. For patients with moderate renal insufficiency (creatinine clearance greater than 0.33 mL/s), the usual dose should be halved.
The drug is not recommended for patients with severe renal insufficiency (creatinine clearance less than 0.33 mL/s).
Hepatic impairment. In patients with hepatic impairment, the usual dose should be reduced by half.
Elderly patients. No dose adjustment is necessary.
Children.
Do not administer the film-coated tablets to children under 3 years of age.
Overdose
No cases of overdose have been reported. In the event of an overdose, symptomatic treatment should be administered.
Side Effects
Allergic reactions: skin rashes and itching, which resolve quickly after discontinuation of the medication; allergic reactions accompanied by thrombocytopenia.
Gastrointestinal system: dyspeptic symptoms (nausea, vomiting, loss of appetite) may occur but can be prevented by taking the medication with food.
Nervous system: headache, ataxia, paresthesia, polyneuropathy.
Hepatobiliary system: decreased transaminase levels, impaired liver function.
Urinary system: decreased plasma uric acid levels.
Other: tachycardia, general weakness.
Side effects usually resolve on their own after discontinuation of the medication.
Shelf life
4 years.
Do not use the medication after the expiration date printed on the package!
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 tablets per blister pack; 5 blister packs per box.
Dispensing Category
By prescription only.
Manufacturer
Public Joint-Stock Company “Scientific and Production Center ‘Borshchahivsky Chemical and Pharmaceutical Plant’.”
Similar products
Products from the same category












